Expanded Partnership Increases Support for Drug Discovery

01/18/2017

We have expanded our partnership with the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to accelerate translation of innovative research efforts for Alzheimer’s disease. By leveraging our combined expertise, investment, and resources, Harrington Discovery Institute and the ADDF will advance Alzheimer’s disease drug discovery projects of great promise in academic institutions nationwide.

“Our mission is to find cures for these degenerative diseases, and this partnership increases funding for innovative research and helps transform early discovery into medicines for patients who really need them,” said Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of Alzheimer’s Drug Discovery Foundation.

The keystone of the collaboration is the ADDF-Harrington Scholar Award, which provides funding and drug development support to both MD and PhD scientists across the United States, to help advance discovery into the clinical realm. Grantees receive:

  • Financial support up to $600,000 over two years
  • Drug development and project management support through Harrington Discovery Institute’s Innovation Support Center

“We are so pleased to enhance our partnership with the ADDF and further support groundbreaking Alzheimer’s disease research,” commented Dr. Jonathan Stamler, MD, President, Harrington Discovery Institute. “Millions of patients and families in the US and around the world are eager for effective treatments. The ADDF has shown a sense of urgency that has made us a better organization, and we share their commitment to advancing neurological discoveries of great promise.”  

Letters of intent for the Scholar Award will be accepted through March 17, 2017 and up to three grantees will be announced in October. Apply online at AlzDiscovery.org/RFPs.